Abstract
Background
Obesity is often associated with fatty liver (FL). In most cases, bright liver at ultrasound (US) and increased alanine aminotransferase (ALT) and gamma-glutamyltranspeptidase (GGT) levels are considered the hallmarks of nonalcoholic fatty liver disease (NAFLD). Insulin resistance (IR) is the main link between obesity and NAFLD. The use of the Bioenterics® intragastric balloon (BIB) is a safe procedure either for inducing a sustained weight loss with diet support or for preparing those patients who are candidates for bariatric surgery. The aim of the study was to investigate whether the weight loss induced by intragastric balloon might improve IR and liver enzymes. The presence or absence of FL at US and the influence of a body mass index (BMI) decrease ≥10% after BIB (ΔBMI ≥ 10%) were also considered.
Methods
One hundred and three consecutive obese (BMI > 30 kg/m2) patients (38 males/65 females; mean age 41.3, range 20–63 years) underwent BIB insertion under endoscopic control. The BIB was removed 6 months later. US, clinical, and routine laboratory investigations were performed before and after BIB. IR was calculated by the homeostasis model assessment (HOMA-IR > 2.5). Exclusion criteria were hepatitis B virus positive, hepatitis C virus positive, alcohol consumption >30 g/day, history of hepato-steatogenic drugs, and type 1 diabetes.
Results
Ninety-three patients were eligible for the study. The BMI significantly decreased in all investigated patients, and it was ≥10% in 59% of the patients. FL was seen at US in 70%, impaired fasting blood glucose was present in 13%, ALT exceeded the normal limit in 30.1%, GGT exceeded the normal limit in 15%, and HOMA-IR was >2.5 in 85%. Median HOMA-IR decreased significantly in FL (4.71 vs 3.10; p < 0.05) and non-FL (3.72 vs 2.81; p < 0.01) groups. Median ALT decreased significantly in the FL group (31.5 vs 24; p < 0.001) and GGT significantly decreased in the FL group (31 vs 23.5; p < 0.05). In the FL group with ΔBMI ≥ 10%, the median values of HOMA-IR (4.95 vs 2.69; p < 0.05), ALT (30 vs 23; p < 0.01), and GGT (28 vs 20; p < 0.001) significantly decreased after BIB. In the non-FL group, HOMA-IR values significantly decreased (4.07 vs 2.36; p < 0.01) in patients with a ΔBMI ≥ 10%; ALT and GGT did not significantly decrease.
Conclusions
Weight loss induced by intragrastric balloon reduces IR. The ALT and GGT decrease suggests an improvement in hepatic damage. The benefit depends on the decrease of BMI higher than 10%.
Similar content being viewed by others
References
Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and metabolic syndrome. Hepatology. 2003;37:917–23.
Bugianesi E, McCullogh AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42:987–1000.
Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2006;91:4753–61.
Wallace TM, Utzschneider KM, Tong J, et al. Relationship of liver enzymes to insulin sensitivity and intra-abdominal fat. Diabetes Care. 2007;30:2673–8.
Hui JM, Hodge, A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology. 2004;40:46–54.
Marchesini G, Avagnina S, Barantani EG, et al. Aminotrasferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J Endocrinol Invest. 2005;28:333–9.
Burgert TS, Taksaly SE, Dziura J, et al. Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab. 2006;91:4287–94.
Chang Y, Ryu S, Sung E, et al. Higher concentrations of alanine aminotrasferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem. 2007;53:686–92.
Bellentani S, Delle Grave R, Suppini A, Marchesini G, and the Fatty Liver Italian Network (FLIN). Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology. 2008;47:746–54.
Wolf AM, Beisiegel U. The effect of loss of excess weight on the metabolic risk factors after bariatric surgery in morbidly and super-obese patients. Obes Surg. 2007;17:910–9.
Mathus-Vligen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance and efficacy of 1-year balloon treatment followed by 1-year balloon-free follow-up. Gastrointest Endosc. 2005;61:19–27.
Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from plasma fasting glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.
Palmentieri B, de Sio I, La Mura V, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis. 2006;38:485–9.
Genco A, Cipriano M, Bacci V, et al. Bioenterics® Intragastric Ballon (BIB®): a short-term double-bind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes. 2006;30:129–33.
Rossi A, Bersani G, Ricci G, Petrini C, De Fabritiis G, Alvisi V. Intrgastric balloon insertion increases the frequency of erosive esophagitis in obese patients. Obes Surg. 2007;17:1346–9.
Hickam IJ, Johnsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminostransferase, fasting insulin, and quality of life. Gut. 2004;53:413–9.
Al-Momen A, El-Mogy I. Intragastric balloon for obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2005;15:101–5
Dixon JB, Bhathal PS, O’Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl trasferase concentrations are associated with histologic improvement. Obes Surg. 2006;16:1278–86.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ricci, G., Bersani, G., Rossi, A. et al. Bariatric Therapy with Intragastric Balloon Improves Liver Dysfunction and Insulin Resistance in Obese Patients. OBES SURG 18, 1438–1442 (2008). https://doi.org/10.1007/s11695-008-9487-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11695-008-9487-x